A Long-term Safety Follow-up Study of L-CsA Therapy for Patients Who Participated in Study 12011.201 and Volunteered to Continue or to Cross-over to L-CsA Inhalation Therapy
Phase of Trial: Phase III
Latest Information Update: 05 Sep 2019
Price : $35 *
At a glance
- Drugs Ciclosporin (Primary)
- Indications Bronchiolitis obliterans
- Focus Adverse reactions
- Sponsors PARI Pharma GmbH
- 03 Sep 2013 Status changed from recruiting to discontinued as reportedby ClinicalTrials.gov record.
- 03 Sep 2013 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health: NCT01439958).
- 10 Aug 2013 This trial has been suspended in Germany, according to the European Clinical Trials Database.